Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Efavirenz Teva

Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11

HOS-215280 · Präparat HOS-155418

10 Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with (dose) Cmax, Cmin with confidence efavirenz intervals if availablea (mechanism) Cmin: ↓ 44% reduction of boceprevir trough Efavirenz: concentrations has not been AUC: ↔ 20% directly assessed. Cmax: ↔ 11% (CYP3A induction - effect on boceprevir) *0-8 hours No effect (↔) equals a decrease in mean ratio estimate of ≤20% or increase in mean ratio estimate of ≤25% Telaprevir/efavirenz Telaprevir (relative to If efavirenz and telaprevir are co- (1,125 mg q8h/600 mg once 750 mg q8h): administered, telaprevir 1,125 mg daily) AUC: ↓ 18% (↓ 8 to ↓ 27) every 8 hours should be used. Cmax: ↓ 14% (↓ 3 to ↓ 24) Cmin: ↓ 25% (↓ 14 to ↓ 34)% Efavirenz: AUC: ↓ 18% (↓ 10 to ↓ 26) Cmax: ↓ 24% (↓ 15 to ↓ 32) Cmin: ↓ 10% (↑ 1 to ↓ 19)% (CYP3A induction by efavirenz) Simeprevir/efavirenz Simeprevir: Concomitant administration of (150 mg once daily /600 mg once AUC: ↓71% (↓67 to ↓74) simeprevir with efavirenz resulted daily) Cmax: ↓51% (↓46 to ↓56) in significantly decreased plasma concentrations of simeprevir due Cmin: ↓91% (↓88 to ↓92) to CYP3A induction by efavirenz, Efavirenz: which may result in loss of AUC: ↔ therapeutic effect of simeprevir. Cmax: ↔ Co-administration of simeprevir Cmin: ↔ with efavirenz is not No effect (↔) equals a decrease in recommended. mean ratio estimate of ≤20% or increase in mean ratio estimate of ≤25% (CYP3A4 enzyme induction) Sofosbuvir/velpatasvir ↔sofosbuvir Concomitant administration of ↓velpatasvir sofosbuvir/velpatasvir with efavirenz resulted in a ↔efavirenz reduction (approximately 50%) in the systemic exposure of velpatasvir. The mechanism of the effect on velpatasvir is induction of CYP3A and CYP2B6 by efavirenz. Coadministration of sofosbuvir/velpatasvir with efavirenz is not recommended. Refer to the prescribing information for sofosbuvir/velpatasvir for more information.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) telaprevir (HOS-090618) boceprevir (HOS-090617) velpatasvir (HOS-108929) simeprevir (HOS-086302)